| [1] |
Dasari A, Shen C, Devabhaktuni A, Nighot R, Sorbye H. 2022. Survival according to primary tumor location, stage, and treatment patterns in locoregional gastroenteropancreatic high-grade neuroendocrine carcinomas. The Oncologist 27:299−306 doi: 10.1093/oncolo/oyab039 |
| [2] |
Hung SS. 1989. Small cell carcinoma of the colon. Journal of Clinical Gastroenterology 11:335−39 doi: 10.1097/00004836-198906000-00019 |
| [3] |
Janson ET, Sørbye H, Welin S, Federspiel B, Grønbaek H, et al. 2010. Nordic guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncologica 49:740−56 doi: 10.3109/0284186X.2010.492791 |
| [4] |
Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, et al. 2013. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Annals of Oncology 24:152−60 doi: 10.1093/annonc/mds276 |
| [5] |
Shia J, Tang LH, Weiser MR, Brenner B, Adsay NV, et al. 2008. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? The American Journal of Surgical Pathology 32:719−31 doi: 10.1097/PAS.0b013e318159371c |
| [6] |
Brenner B, Shah MA, Gonen M, Klimstra DS, Shia J, et al. 2004. Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. British Journal of Cancer 90:1720−26 doi: 10.1038/sj.bjc.6601758 |
| [7] |
Eads JR. 2016. Poorly differentiated neuroendocrine tumors. Hematology/Oncology Clinics of North America 30:151−62 doi: 10.1016/j.hoc.2015.09.007 |
| [8] |
Sorbye H, Grande E, Pavel M, Tesselaar M, Fazio N, et al. 2023. European neuroendocrine tumor society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. Journal of Neuroendocrinology 35:e13249 doi: 10.1111/jne.13249 |
| [9] |
Zelen M. 1973. Keynote address on biostatistics and data retrieval. Cancer Chemotherapy Reports 4(2):31−42 |
| [10] |
Faggiano A, Sabourin JC, Ducreux M, Lumbroso J, Duvillard P, et al. 2007. Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features. Cancer 110:265−74 doi: 10.1002/cncr.22791 |
| [11] |
Al-Toubah T, Halfdanarson T, Gile J, Morse B, Sommerer K, et al. 2022. Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms. ESMO Open 7:100364 doi: 10.1016/j.esmoop.2021.100364 |